O'ZBEKISTON AHOLISIDA AAV ASOSIDAGI GEN TERAPIYASI UCHUN TO'SIQ SIFATIDA ANTI-AAV NEYTRALLOVCHI ANTITANALAR: GLOBAL SEROPREVALENS MA'LUMOTLARIGA ASOSLANGAN PROGNOZ VA KLINIK AHAMIYATI
Keywords:
AAV vektorlari, gen terapiyasi, neytrallovchi antitanalar, seroprevalens, immunogenlik, O‘zbekiston populyatsiyasi, klinik skriningAbstract
Adeno-assotsiatsiyalangan virus (AAV) vektorlari gen terapiyasida istiqbolli natijalar ko‘rsatmoqda, ammo bemorlarda oldindan mavjud neytrallovchi antitanalar (NAb) asosiy to‘siqlardan biridir. O‘zbekiston populyatsiyasida bu borada ma’lumotlar deyarli yo‘q. Maqsad — xalqaro tadqiqotlar asosida O‘zbekistonda AAV serotiplariga NAb tarqalish ehtimolini baholash va klinik ahamiyatini aniqlash. Global adabiyotlar tahlili shuni ko‘rsatadiki, NAb seroprevalensiyasi serotip va hududga qarab 30–70% gacha farq qiladi. Epidemiologik o‘xshashliklarga tayanib, O‘zbekistonda ham, ayniqsa AAV2 va AAV9 serotiplariga yuqori immunitet mavjudligi ehtimoli bor. Bu gen terapiyaga nomzod bemorlarni tanlashda oldindan immunologik skrining zarurligini ko‘rsatadi va mintaqaviy klinik strategiyalarni ishlab chiqish uchun asos bo‘ladi.References
1. Chhabra A. et al. Global seroprevalence of neutralizing antibodies against adeno-associated virus serotypes used for human gene therapies. Molecular Therapy - Methods & Clinical Development, 2024
32(3): 101273.
2. Henry B.M. Global meta-analysis of anti-AAV neutralizing antibody seroprevalence: implications for gene therapy eligibility. ASGCT 28th Annual Meeting, 2025
Abstract 458.
3. Iroanya G.I. et al. Pre-Existing Anti-Adeno-Associated Virus Immunity in Gene Therapy: Mechanisms, Challenges, and Potential Solutions. Human Gene Therapy, 2025
36(23-24): 1463-1480.
4. Li C. et al. Pre-existing Anti-AAV9 antibodies in the Chinese healthy and rare disease populations: implications for gene therapy. Journal of Clinical Virology, 2025
354: 199549.
5. Mingozzi F., High K.A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood, 2013
122(1): 23-36.
6. Qin X. et al. Prevalence of Neutralizing Antibodies Against AAV Serotypes 2 and 9 in Healthy Participants from Multiple Centers Across China and Patients with DMD/BMD. Human Gene Therapy, 2024
35(23-24): 969-977.
7. Somanathan S. et al. Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy. Molecular Therapy, 2023
31(3): 616-630.
8. TAb vs NAb comparative analysis. Comparative Analysis of Total Antibody Titer and Neutralizing Antibody Titer: Correlation and Implications for AAV-Based Gene Therapies. ESGCT 2025.
9. Colella P. et al. Emerging issues in AAV-mediated in vivo gene therapy. Molecular Therapy - Methods & Clinical Development, 2018
8: 87-104.
10. Calcedo R. et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. Journal of Infectious Diseases, 2009
199(3): 381-390